Merck Advances $1 Billion Biologics Facility in Wilmington, Delaware

RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD internationally, continues progress on its groundbreaking $1 billion Biologics Center of Excellence in Wilmington, Delaware.

The 470,000-square-foot Merck Wilmington Biotech facility at Chestnut Run Innovation & Science Park (CRISP) is designed to advance biologics innovation, featuring labs, manufacturing, and warehouse spaces for launching and producing cutting-edge therapies, including antibody-drug conjugates (ADCs). It will serve as the primary U.S. production site for KEYTRUDA® (pembrolizumab), Merck’s leading cancer treatment, enhancing domestic supply for American patients. Future expansions are planned to accommodate Merck’s growing biologics lineup.

“Merck Wilmington Biotech embodies our dedication to U.S.-based innovation and job creation, potentially generating thousands of quality positions while localizing production of essential medicines,” stated Robert M. Davis, chairman and CEO of Merck.

This hub will stimulate Wilmington’s biotech economy, initially creating over 500 full-time jobs and 4,000 construction roles, with expansions adding up to 1,500 permanent positions and 26,000 construction jobs. Labs are on track for full operation by 2028, with investigational production beginning in 2030.

Delaware Gov. Matt Meyer noted, “This facility positions Wilmington at the forefront of medical and tech advancements, delivering lasting benefits to our community.”

Near universities in Delaware and Pennsylvania, the site will draw skilled talent and integrate with Merck’s regional operations in New Jersey and Pennsylvania.

Sanat Chattopadhyay, executive vice president and president of Merck Manufacturing Division, added, “CRISP’s vibrant life sciences environment enables collaboration and scalability.”

This investment aligns with Merck’s strategy to fortify U.S. manufacturing, as highlighted in its Q2 2025 earnings report.